TCT 2017: BIOTRONIK's Orsiro Drug-Eluting Stent Shows Low Five-Year Event Rates in BIOFLOW-II RCT and BIOFLOW-III Registry
DENVER, United States and BUELACH, Switzerland, November 2, 2017 - BIOTRONIK's Orsiro1 drug-eluting stent (DES) demonstr…
DENVER, United States and BUELACH, Switzerland, November 2, 2017 - BIOTRONIK's Orsiro1 drug-eluting stent (DES) demonstr…
BIOTRONIK has announced the launch of its Evity cardiac resynchronization therapy pacemaker (CRT-P) in the Japanese mark…
BIOTRONIK has announced the European launch of a new lead for tachycardia therapy that features a helical design for inc…
Physicians presented encouraging interim data on the efficacy of BIOTRONIK’s dedicated lower limb intervention portfolio…
Following recent CE mark approval for BIOTRONIK’s E-Series pacemakers, a UK patient has become the first in Europe to be…
BIOTRONIK announced today that the Magmaris bioresorbable scaffold has received CE mark approval. The first clinically p…
BIOTRONIK has won the Cardiostim Innovation Award in the category “Best Practice Improvement” for its MRI AutoDetect fea…
BIOTRONIK Home Monitoring® received strong endorsements during the Cardiostim scientific session “Improving Patient Outc…
BIOTRONIK, a global leader in cardio- and endovascular medical technology, today announced the launch of CardioMessenger…
Randomized Controlled Trial Establishes Pantera Lux as a Viable Alternative to a Latest Generation Limus Eluting Stent i…